ADP 13612Alternative Names: ADP13612
Latest Information Update: 16 Mar 2017
$50 / €47 *
At a glance
- Originator Almirall S.A.
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Rosacea
Most Recent Events
- 10 Mar 2017 Preclinical trials in Rosacea in Spain (unspecified route) (Almirall pipeline, March 2017)